Swiss industry’s main external risk is shifting from Washington to Beijing, with UBS arguing that China’s industrial rise now poses a larger and more durable challenge than the 39% US tariffs that jolted exporters a year ago.
Swiss exports face China competition, UBS says
That matters because Switzerland’s export model depends on high-value manufacturing in machinery, electrical engineering, chemicals and medtech — the same areas where Chinese companies are moving up the value chain fast. UBS said US tariffs remain a real burden for firms exposed to the American market, but their effect on the broader Swiss economy is manageable because pharmaceuticals, a major export category, is partly shielded by exemptions.
The bank’s point goes beyond trade policy. Tariffs are a familiar, if painful, cost shock that companies can often work around with pricing, supply-chain changes or market diversification. China’s challenge is structural: weaker domestic demand at home and persistent excess industrial capacity are intensifying competition abroad, especially in sectors where Swiss firms have long relied on technological edge, precision and premium pricing.
That is why the warning lands differently for investors. It suggests the more important question is no longer whether Swiss exporters can absorb a round of US tariffs, but whether they can defend margins against a longer cycle of Chinese industrial competition. For listed companies tied to global capital goods, specialty chemicals and medtech, the risk is not just lower demand, but slower pricing power and pressure on return on capital.
Swissmem, the tech-industry lobby, broadly echoed the diagnosis. It described China as both opportunity and threat, and said the country is no longer just a sales market or low-cost production base but an innovation and development centre — and a competitor. Its response was a call for more trade agreements, including with China, and for faster expansion of Switzerland’s power supply so industry can access cheaper electricity.
The political implication is awkward for Bern. Protecting Switzerland from foreign shocks is not just a question of negotiating better access to the US market, but of sustaining the country’s own industrial competitiveness at home. That includes energy costs, regulation and investment conditions — all areas where Swiss firms say they are losing ground to faster-moving rivals.
For now, the message to markets is that the tariff headline risk may be less important than the deeper erosion of Swiss export pricing power in Asia and beyond. If China keeps advancing in the same technology-intensive industries where Switzerland is strongest, the pressure will show up first in margins, then in growth, and eventually in valuations.
| Entity | Gains | Losses |
|---|---|---|
| Swiss pharma exporters | ▲Tariff exemptions | ▼Broad manufacturing peers |
| Chinese industrial firms | ▲Export share, scale | ▼Swiss tech incumbents |
| Swiss consumers/industry | ▲Lower import costs | ▼Higher domestic investment needs |
| Swiss exporters to the US | ▲Selective protection via diversification | ▼Direct tariff exposure |
